Miami was not on the life sciences map five years ago. In 2020, the city hosted roughly a dozen biotech and pharmaceutical companies of any consequence, most of them small contract research organizations serving the Latin American clinical trial market. The idea that Miami would emerge as a serious life sciences cluster would have drawn skepticism from anyone in Boston, San Francisco, or even the Research Triangle. Yet by early 2026, the Miami-Dade metropolitan area is home to more than 85 biotech, pharmaceutical, and life sciences services companies with active operations, and the trajectory shows no sign of plateauing.
This piece draws on 14 life sciences executive placements we completed in the Miami metropolitan area between January 2024 and Q1 2026, supplemented by conversations with founders, CRO executives, and institutional investors who have committed capital to Miami-based biotech ventures. The sample is modest compared to our Boston or San Francisco life sciences datasets, but the patterns are consistent enough to report with confidence.
From 12 to 85+ biotech companies
The growth of Miami’s biotech cluster is not organic in the way that Cambridge or South San Francisco developed over decades of proximity to research universities and NIH-funded laboratories. Miami’s growth has been driven by three forces operating simultaneously: tax-motivated relocation of biotech executives and founders from high-tax states, strategic positioning for Latin American clinical trial access, and targeted incentive programs from Miami-Dade County and the state of Florida that specifically courted life sciences companies beginning in 2021.
The companies that have established Miami operations fall into three distinct categories. First, clinical-stage biotechs founded or relocated by executives who previously operated from Cambridge or the Bay Area — these tend to maintain R&D operations in their original locations while locating executive leadership, commercial operations, and corporate functions in Miami. Second, contract research organizations that serve as operational bridges between US sponsors and Latin American clinical trial sites — a category that has grown from four meaningful CROs in 2020 to over twenty in 2026. Third, immunology and oncology-focused startups that have been specifically attracted by the concentration of diverse patient populations in South Florida, which is valuable for clinical trial enrollment in indications where demographic representation matters for FDA regulatory submissions.
The numbers are striking when laid out sequentially. In 2020, fewer than 12 companies with meaningful biotech operations were based in Miami-Dade. By end of 2022, that number had grown to roughly 35. By end of 2024, it exceeded 65. As of Q1 2026, we count more than 85 active life sciences companies with Miami-based executive teams, laboratory operations, or corporate headquarters. The growth rate has been faster than any comparable US life sciences cluster in the same period, though the absolute size remains small relative to the established hubs.
CRO operations and clinical infrastructure
The CRO story in Miami deserves specific attention because it represents the most structurally durable component of the city’s life sciences ecosystem. Contract research organizations provide the operational backbone of clinical drug development — site management, patient recruitment, data management, regulatory submissions, and pharmacovigilance — and Miami’s geographic position makes it uniquely suited for CRO operations that span the Americas.
The bilingual workforce is the competitive advantage. CRO operations that manage clinical trial sites across the US, Mexico, Brazil, Colombia, Argentina, and Chile require project managers, clinical research associates, and medical monitors who are fluent in both English and Spanish or Portuguese. Miami’s deep bilingual talent pool — a feature of the city’s demographic composition that predates the biotech boom by decades — provides a structural hiring advantage that Boston and San Francisco cannot replicate. Three of our 14 Miami life sciences placements were specifically for CRO leadership roles where bilingual capability was a non-negotiable requirement.
The CRO infrastructure has also attracted global CRO players to establish or expand Miami offices. IQVIA, Parexel, and Medpace all have growing Miami-area operations, primarily focused on Latin American study coordination. These offices create mid-level and senior employment opportunities that feed the broader life sciences talent ecosystem, producing experienced clinical operations professionals who later move to sponsor companies or start their own CROs.
The Latin American clinical trials gateway
Miami’s role as a gateway for Latin American clinical trials is perhaps its most distinctive competitive position in the life sciences landscape. Latin America has become an increasingly important region for global clinical trial enrollment, driven by large treatment-naive patient populations, improving regulatory frameworks in countries like Brazil and Mexico, and cost structures that are 30% to 50% lower than equivalent US or Western European trial sites.
For US-based biotech companies running global Phase 2 or Phase 3 programs, having executive and operational leadership in Miami provides practical advantages that are difficult to replicate from Boston or San Francisco. Time zone alignment with Latin American sites (Miami is in the same time zone as Bogotá and Lima, one hour ahead of Mexico City, and two hours ahead of São Paulo during parts of the year) reduces the coordination friction that characterizes cross-continental clinical programs. Direct flight connectivity from Miami International Airport to virtually every major Latin American city means that clinical operations leaders can visit sites with a level of frequency and ease that is impractical from the northeast or west coast. Cultural fluency in navigating Latin American business relationships, regulatory agencies, and institutional review boards is native to Miami’s professional community in a way it is not in other US life sciences hubs.
We placed two VP-level Clinical Operations executives in Miami in 2025 whose roles were specifically structured around managing Latin American clinical programs. Both roles required fluent Spanish, both required 40%+ travel to LatAm sites, and both were compensated at a premium relative to comparable Clinical Operations roles that were purely US-focused. The LatAm clinical trial management specialization is a genuine and growing niche within the Miami life sciences market.
Immunology and oncology focus areas
The therapeutic areas where Miami has developed the most meaningful concentration are immunology and oncology, and the reason is directly tied to the demographics of South Florida’s patient population. Clinical trials in oncology and immunology increasingly require enrollment of diverse patient cohorts to satisfy FDA guidance on demographic representation in pivotal studies. South Florida’s population is among the most ethnically and racially diverse in the United States, with large Hispanic, Black, and Caribbean communities that are historically underrepresented in clinical research.
This demographic advantage translates directly into enrollment speed. Several biotech companies in our network have reported that their Miami-area clinical trial sites enroll patients 25% to 40% faster than comparable sites in other regions for immunology and oncology indications, specifically because the local population more closely matches the demographic targets required by their protocols. For clinical-stage companies where time to enrollment directly affects time to data readout and time to NDA filing, this enrollment advantage has genuine economic value measured in months of accelerated development timelines.
The immunology focus has been particularly strong. At least eight of the 85+ Miami-based life sciences companies are specifically focused on autoimmune diseases, inflammatory conditions, or immune-oncology, and several have established relationships with the University of Miami Miller School of Medicine’s immunology research programs. The oncology cluster is somewhat broader, spanning solid tumors, hematologic malignancies, and supportive care, with clinical trial networks that leverage both the diverse local patient population and the concentration of oncology treatment centers in the South Florida medical community.
Talent compensation vs. Boston and San Francisco
Life sciences executive compensation in Miami sits below both Boston and San Francisco but is converging faster than most candidates expect. Our 2024–2026 Miami life sciences placement data shows the following benchmarks for senior roles:
VP Clinical Operations: median total compensation of $340K in Miami versus $410K in Boston and $430K in San Francisco. The Miami figure represents approximately 80% of the Boston equivalent, a narrower gap than the 70% ratio we observe in other sectors.
VP Regulatory Affairs: median total compensation of $295K in Miami versus $345K in Boston. This role shows the closest parity of any life sciences function, likely because regulatory expertise is highly specialized and the candidate pool is small regardless of geography.
Director-level roles in clinical research, medical affairs, and commercial operations show Miami compensation at approximately 75% to 85% of Boston equivalents, with the gap narrowing for roles that specifically require bilingual capability or Latin American market experience.
The compensation gap is partially offset by Florida’s lack of state income tax, which at senior compensation levels creates an effective after-tax advantage of $25K to $45K annually compared to Massachusetts (5.0% flat rate) and a larger advantage compared to California (13.3% top rate). For a VP-level executive earning $350K in base salary plus bonus, the Florida tax advantage alone bridges roughly half the gross compensation gap with Boston.
Equity compensation in Miami biotech follows the same patterns as other emerging biotech clusters: earlier-stage companies offer larger equity grants to compensate for lower base salaries and the perceived career risk of joining a non-traditional biotech hub. The median initial equity grant for VP-level hires at clinical-stage Miami biotechs in our dataset was 0.15% to 0.35% of fully diluted shares, compared to 0.08% to 0.20% for comparable roles at Boston-based companies at similar stages.
What comes next for Miami life sciences
Three predictions for the Miami life sciences market over the next 18 to 24 months, based on our current pipeline and market intelligence:
CRO consolidation will accelerate. The rapid growth of small and mid-sized CROs in Miami will attract acquisition interest from larger global CROs seeking to establish or expand their Americas operations platforms. We expect at least two significant CRO acquisitions involving Miami-based companies in the next 18 months, which will further legitimize the market and create liquidity events for early employees.
Academic-industry partnerships will deepen. The University of Miami Miller School of Medicine and Florida International University’s Herbert Wertheim College of Medicine are both actively building translational research programs designed to bridge academic discovery and commercial development. These partnerships will produce a pipeline of early-stage companies that are founded in Miami rather than relocated there — a critical transition for the long-term sustainability of any biotech cluster.
The talent gap will remain the primary constraint. Despite the growth in companies and capital, Miami’s life sciences talent pool remains thin relative to demand, particularly for experienced clinical development, regulatory affairs, and CMC (chemistry, manufacturing, and controls) leaders. Most senior searches we run in Miami still require national candidate outreach and relocation packages. Until the local talent pipeline matures — which requires both time and sustained institutional investment in training programs — talent scarcity will be the binding constraint on the pace of the cluster’s growth.
For professionals considering Miami, the opportunity is genuine but sector-specific. If your career is in clinical operations, regulatory affairs, or commercial leadership with Latin American market experience, Miami offers a combination of growing demand, favorable compensation dynamics after tax adjustment, and a lifestyle proposition that is increasingly competitive with the established hubs. For discovery-stage scientists, computational biologists, or translational researchers, Miami’s infrastructure is not yet at the level where it can support the full range of career options available in Cambridge or South San Francisco. The market is real and growing, but it is not yet complete.
This piece is authored by Malcolm Sheffield, Talent Partner for our Life Sciences & Healthcare practice, with data assembly and review by our Miami office team. Direct contact: malcolm.sheffield@aldensearch.com.